EA
NKTR icon

Emerald Acquisition’s Nektar Therapeutics NKTR Stock Holding History

Emerald Acquisition’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$890K Sell
3,456
-314
-8% -$80.8K ﹤0.01% 2185
2016
Q2 		$804K Buy
+3,770
New +$843K ﹤0.01% 2272

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Emerald Acquisition's NKTR Position: Q3 2016 in Review

Emerald Acquisition reduced its Nektar Therapeutics (NKTR) stake by 8.3% in Q3 2016, selling an estimated $80.8K and leaving 3,456 shares worth $890K. The position accounts for ﹤0.01% of the portfolio, ranked #2185.

Emerald Acquisition first reported a position in NKTR in Q2 2016 and has held it in 2 quarters since. 194 funds tracked by Wall St. Rank hold NKTR as of Q3 2016.

  • Emerald Acquisition held 3,456 shares of Nektar Therapeutics worth $890K as of Q3 2016.
  • Emerald Acquisition sold 314 Nektar Therapeutics shares in Q3 2016, an estimated $80.8K.
  • Nektar Therapeutics made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2185 holding.
  • Emerald Acquisition first reported a position in Nektar Therapeutics in Q2 2016 and has held it in 2 quarters since.
  • 194 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.